RecruitingNot ApplicableNCT06437470

Effect of Blood Flow Restriction Technique After Anterior Cruciate Ligament Reconstruction

Combined Effect Of Blood Flow Restriction Technique And Conventional Physical Therapy Program After Anterior Cruciate Ligament Reconstruction


Sponsor

Cairo University

Enrollment

30 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study will be to evaluate the effect of adding BFR (using 80% of LOP) to the conventional physical therapy program on knee function, functional test, balance, quadriceps and hamstrings muscles strength, thigh muscle girth and knee effusion in rehabilitation after ACLR.


Eligibility

Min Age: 18 YearsMax Age: 35 Years

Inclusion Criteria4

  • Aged from 18-35 years.
  • Underwent an ACLR semitendinosus autograft one-week post-operative
  • Willingness to participate in the intervention and subsequent assessment.
  • BMI from 18.5 to 29.9 kg/m2.

Exclusion Criteria8

  • Insecure graft fixation (due to bone quality, suspension).
  • Active infection.
  • Postsurgical excess knee swelling that may limit exercise performance.
  • ACLR using bone tendon bone (BTB) graft.
  • Any cardiovascular disease such as hypertension.
  • Any lower limb trauma.
  • Hip and ankle pathology.
  • BMI more than 30 kg/m2

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood flow restriction technique

All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising. All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff.


Locations(1)

Faculty of physical therapy - Cairo University

Cairo, Giza Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06437470


Related Trials